CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Cisplatin +1 moredrug
Likely dose
Cisplatin 100 mg/M2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01277744
NCT01277744Phase 2Completed
CompareCT.gov

A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas

M.D. Anderson Cancer Center·interventional·Posted Jan 17, 2011·Updated Jan 13, 2020

In Brief

A Phase 2 clinical trial evaluating Hyperthermic Peritoneal Perfusion (HIPEC) and Cisplatin for Advanced Cancers and Sarcoma. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if heated intra-abdominal cisplatin can help to control abdominal tumors in patients having surgery to remove the tumors. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancers, Sarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 17, 2011
Enrollment StartMay 9, 2011
Primary CompletionFeb 16, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 15.5 years ago

Interventions

Hyperthermic Peritoneal Perfusion (HIPEC)procedure

HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.

Cisplatindrug

100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.